Expand the Use of Poviztra for MASH Indication Following CDSCO Approval - Emcure Pharmaceuticals Ltd

Code BSE: 544210 NSE: $EMCURE Emcure to Expand the Use of Poviztra for MASH Indication Following CDSCO Approval The approval makes the innovator molecule from Novo Nordisk, the first and only GLP-1 receptor agonist approved in India for the treatment of the disease. It enables Emcure and its subsidiaries to offer the new indication through Poviztra®, expanding access to innovator semaglutide for patients living with a progressive liver disease that has long faced limited treatment options. MASH develops when excess fat accumulation in the liver leads to chronic inflammation, fibrosis and progressive liver damage. Closely linked with obesity, type 2 diabetes and other metabolic disorders, the disease is often asymptomatic until advanced stages, making timely diagnosis and intervention critical.